IMMUNOGENICS LLC

Corona Del Mar, CA · Biotech · Private

Latiglutenase, an orally administered dual-enzyme therapeutic that breaks down gluten protein

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · immunogenx.com

Sector: Biotech
Headquarters: Corona Del Mar, CA
Total capital: $7M

Federal grants: $7M; 5 awards · 2019–2021; Rank in peer group#179 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 5 pending

Capital timeline

Latest events

Aug 2021Federal grantHealth and Human S · Phase II · A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$934K
Sep 2020Federal grantHealth and Human S · Phase II · A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$1.9M
Sep 2020Federal grantHealth and Human S · Phase II · A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$978K
Mar 2020Federal grantHealth and Human S · Phase II · A Clinical Study of Latiglutenase as a Treatment for Symptom Reduction for Celiac Disease$2.9M
Aug 2019Federal grantHealth and Human S · Phase II · A Clinical Study of Latiglutenase as a Treatment for Type 1 Diabetics with Celiac Disease$293K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#179 · top 35%
Linked publications#25 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 5

Oct 10, 2019PendingLatiglutenase (ALV003) For Use In The Treatment Of Symptomatic Celiac Disease, Gluten Intolerance Or Gluten SensitivityUSPTOApplication 16463047
Apr 19, 2018PendingMethods And Pharmaceutical Compositions For Treating Celiac Disease And Gluten IntoleranceUSPTOApplication 15833536
Aug 13, 2015PendingPatient Reported Outcome InstrumentUSPTOApplication 14425932

Show all 5 patent records

Latiglutenase (ALV003) For Use In The Treatment Of Symptomatic Celiac Disease, Gluten Intolerance Or Gluten SensitivityOct 10, 2019 · Application 16463047Pending
Methods And Pharmaceutical Compositions For Treating Celiac Disease And Gluten IntoleranceApr 19, 2018 · Application 15833536Pending
Patient Reported Outcome InstrumentAug 13, 2015 · Application 14425932Pending
Treatment Of Symptomatic Celiac Disease, Gluten Intolerance Or Gluten SensitivityApplication PCTUS2017062602Pending
Treatment Of Symptomatic Celiac Disease, Gluten Intolerance Or Gluten SensitivityApplication 62426119Pending

Recent research by its founders

Mo1022 CORRELATION OF SYMPTOMS AND QUALITY OF LIFE IN AN INTERVENTIONAL TREATMENT STUDY FOR CELIAC DISEASE20261 cites
1099 CONTINUOUS COMPOSITE SCORING HISTOLOGIC AND BIOMARKER INDICATORS FOR CELIAC DISEASE20260 cites
Correlation of Quality of Life and Symptoms in an Interventional Treatment Study for Celiac Disease20260 cites

RAFT PHARMACEUTICALS LLCSimilar federal contract value in Biotech · null in contracts
PLUREXA LLCSimilar federal contract value in Biotech · null in contracts
CIRCCURE CORPORATIONSimilar federal contract value in Biotech · null in contracts
AZEVAN PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
CARAVEL BIO, INC.Similar federal contract value in Biotech · null in contracts
Resilient Biotics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.